Six month follow-up after in-dtpa-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study

Nuclear Medicine Communications

Volumn 25, Issue 7, 2004, Pages 683-690

  Stokkel, Marcel P M ^a   Verkooijen, Robbert B T ^a   Bouwsma, Hanneke ^a   Smit, Jan W A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

In octreotide; Therapy; Thyroid cancer

Indexed keywords

INSULIN; PENTETREOTIDE IN 111; TRACER;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTOXICATION; MALE; MEDICAL ASSESSMENT; METASTASIS; PILOT STUDY; PREMEDICATION; SEPSIS; SICKLE CELL ANEMIA; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; PATIENT SELECTION; PENTETIC ACID; PILOT PROJECTS; PROGNOSIS; RADIOPHARMACEUTICALS; THYROGLOBULIN; THYROID NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 3142514286     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000130244.14444.5e     Document Type: Article

References (53)

1. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997; 79:564-573.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306.
3. Roelants V, Nayer PD, Bouckaert A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24:722-727.
4. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998; 138:249-252.
5. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 1998; 37:12-17.
6. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37:1468-1472.
7. Stokkel MP, de Klerk JH, Zelissen PM, Koppeschaar HP, van Rijk PP. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 1999; 26:1606-1609.
8. Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M, Bartenstein P. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 2003; 13:949-958.
9. Kebebew E, Clark OH. Locally advanced differentiated thyroid cancer. Surg Oncol 2003; 12:91-99.
10. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999; 16:34-41.
11. Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996; 78:493-501.
12. Grûning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003; 148:395-402.
13. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000; 41:636-642.
14. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421-1429.
15. Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, de Herder WW, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996; 57(suppl 1):57-61.
16. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999; 10(suppl 2):S23-S29.
17. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996; 81:2541-2544.
18. Görges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001; 11:647-659.
19. Postema PT, de Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ, et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996; 57(suppl 1):36-37.
20. Stokkel MP, Reigman HI, Verkooijen RB, Smit JW. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol 2003; 129:287-294.
21. Stokkel MP, Boot IN, Smit JW. Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of indium-111 octreotide. Q J Nucl Med 2002; 46:331-335.
22. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL. Is there a role for radiation therapy in the management of Hurthle cell carcinoma? Int J Radiat Oncol Biol Phys 2003; 56:1067-1072.
23. Ford D, Giridharan S, McConkey C, Hartley A, Brammer C, Watkinson JC, et al. External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol R Coll Radiol 2003; 15:337-341.
24. Kim TH, Yang DS, Jung KY, Kim CY, Choi MS. Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys 2003; 55:1006-1012.
25. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001; 86:1568-1573.
26. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626-1631.
27. Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 1997; 82:1857-1862.
28. Hoelting T, Duh QY, Clark OH, Herfarth C. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab 1996; 81:2638-2641.
29. Oberg K. Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10(suppl 2):S3-S8.
30. Zlock DW, Greenspan FS, Clark OH, Higgins CB. Octreotide therapy in advanced thyroid cancer. Thyroid 1994; 4:427-431.
31. Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000; 10:177-183.
32. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282.
33. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28:836-846.
34. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000; 44:88-95.
35. − symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 1998; 83:4102-4106.
36. − symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999; 84:3228-3234.
37. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999; 141:443-457.
38. 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000; 21:97-102.
39. deJong M, Breeman WA, Bernard HF, Kooij PP, Slooter GD, van Eijck CH, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 1999; 43:356-366.
40. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000; 44:88-95.
41. 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. South Med J 2000; 93:809-811.
42. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26:1439-1447.
43. 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426-434.
44. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4-GBq (90)Y-DOTATOC. J Nucl Med 2002; 43:610-616.
45. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140:5136-5148.
46. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. New trends in peptide receptor radioligands. Q J Nucl Med 2001; 45:153-159.
47. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002; 8:1781-1807.
48. Kebebew E, Clark OH. Locally advanced differentiated thyroid cancer. Surg Oncol 2003; 12:91-99.
49. Schmutzler C, Schmitt TL, Glaser F, Loos U, Kohrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cell Endocrinol 2002; 189:145-155.
50. Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39:1903-1906.
51. Simon D, Kohrle J, Schmutzler C, Mainz K, Reiners C, Roher HD. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996; 104(suppl 4):13-15.
52. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002; 29:775-782.
53. Eigelberger MS, Wong MG, Duh QY, Clark OH. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer. Surgery 2001; 130:931-935.